325 related articles for article (PubMed ID: 29559288)
1. Prospective Trial Using Internal Pair-Production Positron Emission Tomography to Establish the Yttrium-90 Radioembolization Dose Required for Response of Hepatocellular Carcinoma.
Chan KT; Alessio AM; Johnson GE; Vaidya S; Kwan SW; Monsky W; Wilson AE; Lewis DH; Padia SA
Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):358-365. PubMed ID: 29559288
[TBL] [Abstract][Full Text] [Related]
2. Hepatocellular Carcinoma Tumor Dose Response After
Kappadath SC; Mikell J; Balagopal A; Baladandayuthapani V; Kaseb A; Mahvash A
Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):451-461. PubMed ID: 30191875
[TBL] [Abstract][Full Text] [Related]
3. Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis.
Padia SA; Alessio A; Kwan SW; Lewis DH; Vaidya S; Minoshima S
J Vasc Interv Radiol; 2013 Aug; 24(8):1147-53. PubMed ID: 23792126
[TBL] [Abstract][Full Text] [Related]
4. Histogram Analysis of CT Perfusion of Hepatocellular Carcinoma for Predicting Response to Transarterial Radioembolization: Value of Tumor Heterogeneity Assessment.
Reiner CS; Gordic S; Puippe G; Morsbach F; Wurnig M; Schaefer N; Veit-Haibach P; Pfammatter T; Alkadhi H
Cardiovasc Intervent Radiol; 2016 Mar; 39(3):400-8. PubMed ID: 26216725
[TBL] [Abstract][Full Text] [Related]
5. Microsphere localization and dose quantification using positron emission tomography/CT following hepatic intraarterial radioembolization with yttrium-90 in patients with advanced hepatocellular carcinoma.
Lea WB; Tapp KN; Tann M; Hutchins GD; Fletcher JW; Johnson MS
J Vasc Interv Radiol; 2014 Oct; 25(10):1595-603. PubMed ID: 25156647
[TBL] [Abstract][Full Text] [Related]
6. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
[TBL] [Abstract][Full Text] [Related]
7. Hepatotoxic Dose Thresholds by Positron-Emission Tomography After Yttrium-90 Radioembolization of Liver Tumors: A Prospective Single-Arm Observational Study.
Chan KT; Alessio AM; Johnson GE; Vaidya S; Kwan SW; Monsky W; Wilson AE; Lewis DH; Padia SA
Cardiovasc Intervent Radiol; 2018 Sep; 41(9):1363-1372. PubMed ID: 29651580
[TBL] [Abstract][Full Text] [Related]
8. Radioembolization with
Ho CL; Chen S; Cheung SK; Leung YL; Cheng KC; Wong KN; Wong YH; Leung TWT
Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2110-2121. PubMed ID: 29948107
[TBL] [Abstract][Full Text] [Related]
9. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma.
Allimant C; Kafrouni M; Delicque J; Ilonca D; Cassinotto C; Assenat E; Ursic-Bedoya J; Pageaux GP; Mariano-Goulart D; Aho S; Guiu B
J Vasc Interv Radiol; 2018 Dec; 29(12):1662-1670.e4. PubMed ID: 30217745
[TBL] [Abstract][Full Text] [Related]
10. Quantitative dosimetry for yttrium-90 radionuclide therapy: tumor dose predicts fluorodeoxyglucose positron emission tomography response in hepatic metastatic melanoma.
Eaton BR; Kim HS; Schreibmann E; Schuster DM; Galt JR; Barron B; Kim S; Liu Y; Landry J; Fox T
J Vasc Interv Radiol; 2014 Feb; 25(2):288-95. PubMed ID: 24269792
[TBL] [Abstract][Full Text] [Related]
11. Correlation of Technetium-99m Macroaggregated Albumin and Yttrium-90 Glass Microsphere Biodistribution in Hepatocellular Carcinoma: A Retrospective Review of Pretreatment Single Photon Emission CT and Posttreatment Positron Emission Tomography/CT.
Haste P; Tann M; Persohn S; LaRoche T; Aaron V; Mauxion T; Chauhan N; Dreher MR; Johnson MS
J Vasc Interv Radiol; 2017 May; 28(5):722-730.e1. PubMed ID: 28238581
[TBL] [Abstract][Full Text] [Related]
12. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with
Hermann AL; Dieudonné A; Ronot M; Sanchez M; Pereira H; Chatellier G; Garin E; Castera L; Lebtahi R; Vilgrain V;
Radiology; 2020 Sep; 296(3):673-684. PubMed ID: 32602828
[TBL] [Abstract][Full Text] [Related]
13. Radioembolization With Yttrium-90 Resin Microspheres in Hepatocellular Carcinoma: A Multicenter Prospective Study.
Kim DY; Park BJ; Kim YH; Han KH; Cho SB; Cho KR; Uhm SH; Choe JG; Choi JY; Chun HJ; Lee HC; Gwon DI; Lee KH; Yoon JH; Chung JW; Kim CW; Heo J; Kim JK; Joo YE
Am J Clin Oncol; 2015 Oct; 38(5):495-501. PubMed ID: 24064753
[TBL] [Abstract][Full Text] [Related]
14. Dosimetry based on 99mTc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results.
Garin E; Lenoir L; Rolland Y; Edeline J; Mesbah H; Laffont S; Porée P; Clément B; Raoul JL; Boucher E
J Nucl Med; 2012 Feb; 53(2):255-63. PubMed ID: 22302962
[TBL] [Abstract][Full Text] [Related]
15. Comparison of PERCIST and RECIST criteria for evaluation of therapy response after yttrium-90 microsphere therapy in patients with hepatocellular carcinoma and those with metastatic colorectal carcinoma.
Sager S; Akgün E; Uslu-Beşli L; Asa S; Akovali B; Sahin O; Yeyin N; Demir M; Abuqbeitah M; Gülsen F; Sayman H; Sönmezoglu K
Nucl Med Commun; 2019 May; 40(5):461-468. PubMed ID: 30896544
[TBL] [Abstract][Full Text] [Related]
16. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with
Garin E; Rolland Y; Pracht M; Le Sourd S; Laffont S; Mesbah H; Haumont LA; Lenoir L; Rohou T; Brun V; Edeline J
Liver Int; 2017 Jan; 37(1):101-110. PubMed ID: 27514012
[TBL] [Abstract][Full Text] [Related]
17. Early treatment response evaluation after yttrium-90 radioembolization of liver malignancy with CT perfusion.
Reiner CS; Morsbach F; Sah BR; Puippe G; Schaefer N; Pfammatter T; Alkadhi H
J Vasc Interv Radiol; 2014 May; 25(5):747-59. PubMed ID: 24630751
[TBL] [Abstract][Full Text] [Related]
18. Image-guided personalized predictive dosimetry by artery-specific SPECT/CT partition modeling for safe and effective 90Y radioembolization.
Kao YH; Hock Tan AE; Burgmans MC; Irani FG; Khoo LS; Gong Lo RH; Tay KH; Tan BS; Hoe Chow PK; Eng Ng DC; Whatt Goh AS
J Nucl Med; 2012 Apr; 53(4):559-66. PubMed ID: 22343503
[TBL] [Abstract][Full Text] [Related]
19. Chemoembolic hepatopulmonary shunt reduction to allow safe yttrium-90 radioembolization lobectomy of hepatocellular carcinoma.
Gaba RC; Vanmiddlesworth KA
Cardiovasc Intervent Radiol; 2012 Dec; 35(6):1505-11. PubMed ID: 22526098
[TBL] [Abstract][Full Text] [Related]
20. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.
Salem R; Lewandowski RJ; Kulik L; Wang E; Riaz A; Ryu RK; Sato KT; Gupta R; Nikolaidis P; Miller FH; Yaghmai V; Ibrahim SM; Senthilnathan S; Baker T; Gates VL; Atassi B; Newman S; Memon K; Chen R; Vogelzang RL; Nemcek AA; Resnick SA; Chrisman HB; Carr J; Omary RA; Abecassis M; Benson AB; Mulcahy MF
Gastroenterology; 2011 Feb; 140(2):497-507.e2. PubMed ID: 21044630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
